HeimALC • NYSE
add
Alcon AG
Við síðustu lokun
83,40 $
Dagbil
82,61 $ - 83,23 $
Árabil
74,30 $ - 101,10 $
Markaðsvirði
38,18 ma. CHF
Meðalmagn
768,86 þ.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
SWX
Í fréttum
Fjármál
Rekstrarreikningur
Tekjur
Nettótekjur
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Tekjur | 2,45 ma. | 5,37% |
Rekstrarkostnaður | 1,04 ma. | -1,42% |
Nettótekjur | 263,00 m. | 28,92% |
Hagnaðarhlutfall | 10,72 | 22,37% |
Hagnaður á hvern hlut | 0,81 | 22,73% |
EBITDA | 620,00 m. | 19,23% |
Virkt skatthlutfall | 9,93% | — |
Efnahagsreikningur
Heildareignir
Heildarskuldir
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Reiðufé og skammtímafjárfestingar | 1,99 ma. | 88,78% |
Heildareignir | 30,36 ma. | 3,38% |
Heildarskuldir | 8,97 ma. | -2,65% |
Eigið fé alls | 21,39 ma. | — |
Útistandandi hlutabréf | 494,60 m. | — |
Eiginfjárgengi | 1,93 | — |
Arðsemi eigna | 2,76% | — |
Ávöxtun eigin fjár | 3,16% | — |
Peningaflæði
Breyting á handbæru fé
| (USD) | sep. 2024info | Breyting á/á |
|---|---|---|
Nettótekjur | 263,00 m. | 28,92% |
Handbært fé frá rekstri | 747,00 m. | 41,75% |
Reiðufé frá fjárfestingum | -483,00 m. | -217,76% |
Reiðufé frá fjármögnun | -81,00 m. | -910,00% |
Breyting á handbæru fé | 194,00 m. | -50,26% |
Frjálst peningaflæði | 661,88 m. | 69,93% |
Um
Alcon Inc. is a Swiss-American pharmaceutical and medical device company specializing in eye care products. It has a paper headquarters in Geneva, Switzerland but its operational headquarters are in Fort Worth, Texas, United States, where it employs about 4,500 people.
Alcon was a subsidiary of Novartis until April 2019, when it was spun out into a separate publicly traded company. Alcon itself has a number of subsidiaries, including Aerie Pharmaceuticals, focused on therapies for glaucoma and other diseases of the eye, and WaveLight, which develops and manufactures laser eye surgery technologies. Wikipedia
Framkvæmdastjóri
Stofnsett
1945
Höfuðstöðvar
Vefsvæði
Starfsfólk
25.000
